PSYCHOLOGICAL AND BEHAVIORAL REACTIONS WHEN PATIENTS WITH RHEUMATOID ARTHRITIS START BIOLOGICAL DMARDS

被引：0
|
作者：
Motonaga, T. [1 ]
Mori, M. [2 ]
Mabuchi, M. [3 ]
Sakai, Y. [4 ]
Iijima, Y. [5 ]
Hidaka, T. [6 ]
Kameda, H. [7 ]
Kawahito, Y. [8 ]
机构：
[1] Teikyo Univ, Tokyo, Japan
[2] Jikei Univ, Sch Med, Tokyo, Japan
[3] Tokyo Univ Agr & Technol, Tokyo, Japan
[4] Atomi Univ, Tokyo, Japan
[5] Nippon Koukan Hosp, Kawasaki, Kanagawa, Japan
[6] Zenjinkai Shimin No Mori Hosp, Miyazaki, Japan
[7] Toho Univ, Tokyo, Japan
[8] Kyoto Prefectural Univ Med, Kyoto, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.5323
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1226
引用
收藏
页码：1344 / 1345
页数：2
相关论文
共 50 条
  • [41] Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment
    Miwa, Yusuke
    Takahashi, Ryo
    Ikari, Yuzo
    Maeoka, Airi
    Nishimi, Shinichiro
    Oguro, Nao
    Hayashi, Tomoki
    Hatano, Mika
    Isojima, Sakiko
    Yanai, Ryo
    Kasama, Tsuyoshi
    Toyoshima, Yoichi
    Inagaki, Katsunori
    Sanada, Kenji
    INTERNAL MEDICINE, 2017, 56 (08) : 903 - 906
  • [42] THE IMPACT OF AGE ON DISCONTINUATION OF BIOLOGIC DMARDs IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Rivera Teran, V.
    Sicsik, S.
    Vega-Morales, D.
    Irazoque-Palazuelos, F.
    Miranda, D.
    Casasola, J. C.
    Carrilo, S.
    Pena, A.
    Castillo Ortiz, A.
    Munoz-Monroy, O. E.
    Duran Barragan, S.
    Paz, A.
    Torres Valdez, E.
    Valdes Corona, L. F.
    Xibille Friedmann, D. X.
    Zamora, E.
    Ramos, A.
    Santana, N.
    Vazquez, M.
    Guerrero, F.
    Zepeda, C.
    Alvarado, K.
    Rivera, M.
    Alpizar-Rodriguez, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 559 - 560
  • [43] ADHERENCE TO DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS - A MULTICENTER OUTPATIENT STUDY
    Krueger, K.
    Kellner, H.
    Welcker, M.
    Schaum, T.
    Haug-Rost, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 223 - 224
  • [44] Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis
    Tanaka, Yoshiya
    RHEUMATOLOGY, 2016, 55 : 15 - 22
  • [45] Biological treatment in rheumatoid arthritis: when to stop?
    Kirwan, John R.
    Boers, Maarten
    LANCET, 2014, 383 (9914): : 288 - 289
  • [46] Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook
    Sonomoto, Koshiro
    Tanaka, Yoshiya
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (11) : 1325 - 1342
  • [47] Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis
    Zhang, Ling Ling
    Yang, Sen
    Wei, Wei
    Zhang, Xue Jun
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (11): : 531 - 538
  • [48] A systematic review of cost-effectiveness analyses of biological DMARDs in rheumatoid arthritis
    Richard, L.
    Brown, M.
    VALUE IN HEALTH, 2007, 10 (06) : A245 - A246
  • [49] The increased cardiovascular risk in rheumatoid arthritis: when does it start?
    Michael T Nurmohamed
    Arthritis Research & Therapy, 12
  • [50] Cardiovascular risk in rheumatoid arthritis: when does it really start?
    Nurmohamed, Michael T.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (04) : 429 - 432
12345